Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)

CPL-01, for Non-Opioid Treatment of Post-Operative Pain, Garners Publication of Clinical Data in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue Models Supporting Pharmacokinetics and Safety SAN DIEGO, Oct. 26, 2022 /PRNewswire/ — Cali Biosciences Co., Ltd….

Click here to view original post